$Elevation Oncology(ELEV.US)$$Merrimack Pharmaceuticals(MACK.US)$Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT Newswires· 2 mins ago Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution. The milestone payment was due from Ipsen after the US Food and Drug Administration approved Onivyde as a first-line...
Chairman Gary Crocker highlighted that interest income on cash and short term investments helped offset a significant portion of Q3 operating expenses. He also noted the company keeps observing developments in Ipsen's Onivyde(R) and Elevation's seribantumab programs.
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week. Top Medical News of the Week $Moderna(MRNA.US)$'s new Covid booster triggered a stronger immune response against omicron BA.5 and also appears to work against the emerging BQ.1.1 subvariant, according to the company. The U.S. Covid public health emergency will remain in place past Jan. 11 after the federal government did no...
Jaguar8 : 我喜歡里程碑付款,但是解散壓了它
Trytosaveabit樓主 Jaguar8: 是啊!我相信你是對的